Posted by Surbhi on June 29 2026 at 05:01 PM
public
KRAS inhibitor breakthroughs — the targeted therapies addressing the most frequently mutated oncogene in human cancers (present in approximately 25% of all tumors) that was considered pharmacolog...
The cancer gene therapy market represents one of the most dynamic and innovation-driven areas of modern oncology, centered on the use of genetic material to modify, repair, silence, or introduce ...
